MPO was one of the plasma biomarkers assessed as a potential novel indicator of doxorubicin-induced cardiotoxicity in breast cancer patients in a study of 17 patients with triple-negative breast cancer patients and 17 healthy individuals [95]. Here, MPO is linked to triple-negative breast carcinoma.